FIRMAGON Drug Patent Profile

Which patents cover Firmagon, and when can generic versions of Firmagon launch?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eight patent family members in twenty-four countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Firmagon

Firmagon was eligible for patent challenges on December 24, 2012.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2029. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (degarelix acetate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for FIRMAGON

International Patents:	108
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	57
Patent Applications:	3,750
Drug Prices:	Drug price information for FIRMAGON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FIRMAGON
What excipients (inactive ingredients) are in FIRMAGON?	FIRMAGON excipients list
DailyMed Link:	FIRMAGON at DailyMed

See drug prices for FIRMAGON

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FIRMAGON

Constraining patent/regulatory exclusivity:

9,579,359

NDA:

022201

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FIRMAGON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eli Lilly and Company	Phase 1/Phase 2
Bayer	Phase 1/Phase 2
Praful Ravi	Phase 1/Phase 2

See all FIRMAGON clinical trials

Paragraph IV (Patent) Challenges for FIRMAGON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRMAGON	Powder for Injection	degarelix acetate	80 mg/vial and 120 mg/vial	022201	1	2019-12-20

US Patents and Regulatory Information for FIRMAGON

FIRMAGON is protected by nine US patents.

This potential generic entry date is based on patent 9,579,359.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	9,579,359
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes	11,826,397
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	10,729,739
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	12,533,387
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes	12,514,898
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	11,766,468
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes	10,729,739

Expired US Patents for FIRMAGON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008	5,925,730
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008	5,925,730

International Patents for FIRMAGON

When does loss-of-exclusivity occur for FIRMAGON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Jordan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FIRMAGON around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009213748
Australia	2009213751
Brazil	PI0908127
Brazil	PI0908129
Canada	2714444
Canada	2714445
Canada	3235099

Supplementary Protection Certificates for FIRMAGON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003774	CA 2009 00022	Denmark
1003774	91585	Luxembourg		PRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
1003774	PA2009005	Lithuania		PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
1003774	SPC020/2009	Ireland		SPC020/2009: 20091119, EXPIRES: 20230412
1003774	300395	Netherlands		300395, 20180413, EXPIRES: 20230412
1003774	09C0028	France		PRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
1003774	PA2009005,C1003774	Lithuania		PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217

FIRMAGON (degarelix) Market Dynamics and Financial Trajectory: Exclusivity, Competition, Pricing, and Revenue Risks

Last updated: June 22, 2026

Firmagon (degarelix; Ferring) is a GnRH antagonist used for advanced prostate cancer and is sold as a monthly subcutaneous injection. Its financial trajectory has been shaped by (1) loss of core brand exclusivity dynamics over time in key markets, (2) competition from GnRH agonists and competing androgen deprivation regimens, and (3) payer pressure on injection-based therapies. On the U.S. IP side, the practical commercial risk is generics and authorized competition that can emerge after patent and regulatory exclusivity windows close, alongside follow-on label or formulation patents that can delay entry in specific presentations.

At the U.S. regulatory level, Firmagon is an FDA-approved drug product with a defined Orange Book patent list that sets the baseline for Paragraph IV risk and generic entry timing. For global commercialization, the market behavior is driven by tendering, hospital formularies, and reimbursement policies that tend to favor lower acquisition-cost regimens after brand protections erode.

---

How has Firmagon (degarelix) performed commercially in recent years?

Answer: Firmagon has sustained market presence as an established prostate cancer androgen deprivation therapy, but growth is typically constrained by (a) competitor share capture among GnRH agonists, (b) payer cost containment on injectable oncology drugs, and (c) the gradual erosion of brand advantage as exclusivity-related barriers narrow.

What do the latest sales drivers look like?

• Dose and regimen adherence: Firmagon is dosed by loading and maintenance schedules, creating reliance on treatment persistence and clinic administration workflows.
• Site-of-care economics: Like many oncology injectables, sales are influenced by hospital purchasing cycles, specialty pharmacy channels (where applicable), and patient case mix in urology and oncology practices.
• Line-of-therapy positioning: Firmagon’s share is shaped by how clinicians sequence androgen deprivation options relative to competing GnRH agonists, especially where clinical pathways consider rapid testosterone suppression versus other initiation approaches.

What revenue headwinds matter most for Firmagon?

• Price and rebate compression: U.S. and EU payer pressure typically reduces net price through rebates, discounts, and tender outcomes after competitive threats intensify.
• Competition from GnRH agonists: Leuprolide and related agonists are standard of care in many settings, often offered at lower net costs.
• Generic entry risk: When patent or exclusivity barriers weaken, generic or authorized products can trigger sharp revenue share changes even before full market penetration.

---

When does Firmagon lose exclusivity and when can generics enter the US?

Answer: Generic entry timing is governed by the Orange Book-listed patent expirations and any applicable FDA exclusivities (and by litigation/settlement outcomes where they occur). Once the last relevant listed patent and exclusivity protections end for a given dosage form, ANDA filers can seek approval, subject to the procedural timeline and any legal stays.

What is the exclusivity framework that governs Firmagon’s US launch risk?

1. Orange Book listed patents (composition, formulation, method-of-use, or manufacturing claims) tied to the approved NDA.
2. Statutory FDA exclusivities that can delay ANDA approval (for example, new clinical investigations, pediatric exclusivity, or patent-linked exclusivity), when applicable to the specific product and regulatory history.
3. Patent litigation over Paragraph IV certifications, which can trigger a 30-month stay and can lead to court decisions or settlements that define “at-risk” launch dates.

How does Paragraph IV litigation affect the generic calendar?

Paragraph IV challenges are the key legal inflection points for market entry. A settlement can shift the effective launch date by defining “skinny label” or design-around scope, including:

• timing of launch,
• scope of dosage strength and schedule,
• labeling carve-outs,
• distribution channel constraints.

(For Firmagon, the exact dates must be determined by the Orange Book patent list for each dosage form and the status of any litigations tied to those patents.)

---

What patents protect Firmagon formulations and delivery schedule in the US (Orange Book scope)?

Answer: Firmagon’s Orange Book protection typically spans product-specific patents covering composition and/or dosage form, and may include method-of-use and/or manufacturing/process claims that affect ANDA design-around viability.

Which patent categories tend to matter for androgen deprivation injectable products?

• Formulation and composition: protects the specific drug product composition and stabilization or delivery system design.
• Manufacturing/process: protects sterile production conditions, particle handling, or process parameters.
• Method-of-use: protects specific clinical regimens such as dosing schedules or patient subgroups.
• Device-like adjunct protections: less common for pure SC injections but can appear when the product includes specific administration features.

How many patents cover Firmagon’s relevant strengths and forms?

Answer: The number of Orange Book listings for Firmagon depends on the number of patent families linked to each strength and any continuation filings. Patent-family size can increase over time through new formulation or process patents filed by the brand owner.

---

What generic entry risks exist for Firmagon’s degarelix injections?

Answer: The primary entry risks are tied to (1) the scope and strength of Orange Book-listed patents that survive to the proposed generic approval date, and (2) whether ANDA filers can credibly certify “no claim” or “invalid/unenforceable” for each listed patent.

Where the risk concentrates

• Strength-specific risk: if one strength has fewer enforceable patents than another, launch calendars can split by strength.
• Method-of-use risk: a generic may seek approval with a carve-out label or a narrower indication that avoids infringement.
• Manufacturing/process risk: even if the active ingredient is the same, a process claim can block straightforward generic manufacturing unless design-arounds are validated.

---

How do Firmagon’s market dynamics compare with competing androgen deprivation therapies?

Answer: Firmagon competes with GnRH agonists (monthly and 3-month depot options) and with other androgen deprivation strategies. In most formularies, GnRH agonists win on acquisition cost and dosing convenience, while Firmagon’s differentiated value has been linked to faster testosterone suppression at initiation and a distinct dosing approach.

Competitive basis in US and EU formularies

• Cost per treated member: tends to drive selection once payer contracting tightens.
• Administration preference: depot injectables can be easier for scheduling than monthly SC injections.
• Clinical pathway fit: initiation speed and management of flare concerns can affect choice at treatment start.

How does competition shift after exclusivity erosion?

After patent and exclusivity windows close, the market often shifts through:

• immediate discounting and rebate renegotiations by the brand,
• rapid uptake by pharmacy and infusion centers depending on supply and contract terms,
• consolidation into preferred formulary regimens.

---

What settlement agreements and litigation events drive Firmagon launch timing?

Answer: Generic launch timing hinges on the presence or absence of Paragraph IV disputes and the outcomes. Settlements can create delayed entry dates even when patents technically expire, by using licensing or consent judgment terms.

What typical deal structures show up in Firmagon-type cases?

• Trigger-based entry: generics enter on a fixed date or after specified patent expiry.
• Carve-outs: limited indication labeling to reduce infringement exposure.
• Licensing: brand receives royalties in exchange for earlier or guaranteed entry.

(Exact Firmagon-specific litigation and settlement terms must be sourced from the listed district court docket events and related FDA ANDA litigation records tied to Orange Book patents.)

---

What is Firmagon’s FDA status and how does it affect market access?

Answer: Firmagon is an FDA-approved injectable product for advanced prostate cancer. Its approval status determines which formulations are commercially available and whether generic competitors can submit ANDAs under the Hatch-Waxman framework.

What FDA pathway details matter for commercial timing?

• ANDA approval mechanics: requires bioequivalence and adequate labeling alignment.
• Labeling and indication scope: dictates whether a generic can be substituted at the pharmacy level and how it is reimbursed under plan formularies.
• Exclusivity and patent listings: determine whether FDA can approve an ANDA before a particular date.

---

How do manufacturing and supply constraints affect Firmagon revenue?

Answer: Injectable oncology products are sensitive to manufacturing capacity, sterile fill-finish throughput, and quality system events. Even when patents expire, a brand with stable supply can defend share longer through uninterrupted availability and contract reliability.

What supply factors are most relevant

• Sterile manufacturing capacity for lyophilized or reconstituted injection workflows (if applicable to the specific product form).
• Batch release timing and quality investigations that can drive temporary allocation.
• Long lead-time components and packaging for injection administration.

---

What geographic dynamics shape Firmagon’s global revenue?

Answer: Global revenue behavior is driven by market-specific reimbursement regimes and tendering policies, with U.S. net price and share responding strongly to patent expiry and generic uptake, while EU revenues react to hospital tender structures and national reimbursement decisions.

How protection and competition differ by region

• U.S.: Orange Book and Paragraph IV litigation create a legally defined entry calendar.
• EU: patent status and marketing authorization exclusivity influence competitive entry, often with country-specific reimbursement timing.
• Emerging markets: tenders and local regulatory approvals can create different uptake speeds, even with similar IP expiry.

---

What is the strength of Firmagon’s patent estate for business risk planning?

Answer: Patent estate strength for Firmagon is evaluated by (1) which Orange Book patents cover the approved drug product, (2) the time to their expiration, and (3) whether any patents are already weakened by litigation outcomes or survived intact through appellate stages.

Patent strength indicators used in licensing and litigation strategy

• Number of surviving independent claims per patent family.
• Claim scope breadth for composition/formulation versus process and method-of-use.
• Litigation history by patent family and enforcement posture.
• Compatibility of design-around options with manufacturing realities.

---

How might a generic or authorized version of Firmagon alter pricing and reimbursement?

Answer: Entry typically triggers rapid net price reductions, formulary status changes, and increased payer utilization of the lowest-cost substitute. Uptake depends on:

• whether interchangeability is permitted at the plan level,
• whether the generic is fully labeled for all indications,
• tender contract awarding rules for injectable products.

Typical market reaction patterns

• Contract-driven: hospital purchasing switches to the lowest-cost equivalent through tenders.
• Rebate-driven: brand adjusts rebates to protect share where formularies remain mixed.
• Treatment-start effects: even with continued use by existing patients, new starts often shift first to the lowest-cost option.

---

Key Takeaways

• Firmagon’s financial trajectory is primarily driven by androgen deprivation therapy competitive dynamics and payer cost containment, with brand advantage narrowing over time as patent and exclusivity barriers erode.
• U.S. generic entry timing depends on Orange Book patent expirations and any Paragraph IV litigation or settlements tied to those listings.
• The biggest revenue risks are net price compression, rebate pressure, and generic/authorized competition that can shift formulary status rapidly.
• Market share and persistence are influenced by dosing convenience and site-of-care contracting, not only clinical differentiation.

---

FAQs

1. What Paragraph IV filings are associated with Firmagon’s Orange Book patents?
2. Which Firmagon dosage strengths and presentations have the most enforceable patent coverage?
3. How do biosimilar pathways apply to Firmagon (degarelix), if at all?
4. What labeling differences most affect generic substitution for Firmagon in the US?
5. How do hospital tender contracts in major EU markets typically treat degarelix injections after generic entry?

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-23).
2. FDA drug labeling for Firmagon (degarelix) and related regulatory history. (Accessed 2026-06-23).